A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refactory Chronic Lymphocytic Leukemia (CLL) Prolymphocytic Leukemia (PLL), or Small Lymphocytic Leukemia (SLL)
Sponsor: Cambridge Antibody Technology
Terminated
The study is terminated early due to unavailability of investigational product.
Other terminated trials from Cambridge Antibody Technology
More terminations from Cambridge Antibody Technology
This PHASE1 trial investigates Leukemia, Lymphoma, Chronic Lymphocytic and Leukemia, Prolymphocytic Leukemia, Small and is currently terminated or withdrawn. Cambridge Antibody Technology leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 4 earlier versions
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
May 2017 — Aug 2017 [monthly]
Terminated PHASE1
Status: Suspended → Terminated
-
Feb 2017 — May 2017 [monthly]
Suspended PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge Antibody Technology
- MedImmune LLC
For direct contact, visit the study record on ClinicalTrials.gov .